Compare HBCP & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | IVVD |
|---|---|---|
| Founded | 1908 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.9M | 437.1M |
| IPO Year | 2008 | 2021 |
| Metric | HBCP | IVVD |
|---|---|---|
| Price | $66.16 | $0.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.50 | $8.75 |
| AVG Volume (30 Days) | 54.7K | ★ 4.5M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | 29.01 | ★ 79.02 |
| EPS | ★ 1.45 | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | $3.97 | $41.42 |
| P/E Ratio | $46.30 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $49.49 | $0.49 |
| 52 Week High | $68.65 | $3.07 |
| Indicator | HBCP | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 38.09 |
| Support Level | $62.28 | N/A |
| Resistance Level | N/A | $1.25 |
| Average True Range (ATR) | 1.59 | 0.11 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 56.75 | 34.84 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.